Zema CL¹, Valdecantos WC¹, Weiss J², Krebs B², Menter AM³

Characteristics and Treatment of Generalized Pustular Psoriasis Flares in the US ¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; ²Optum, Minneapolis, MN, USA; ³Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA

BACKGROUND & STUDY OBJECTIVES

- Generalized pustular psoriasis (GPP) is a rare, but severe multisystem, chronic inflammatory disease characterized by sudden and widespread eruption of sterile pustules of varying severity.¹⁻³
- Pustules during and after a GPP flare can often last for many weeks and can lead to lifethreatening complications often requiring emergency care.¹⁻⁴
- The most recent estimate of mortality is 4.2% from a nationwide study of hospitalized patients with GPP in Japan.⁵
- There is growing evidence focused on understanding the overall disease burden and treatment patterns in patients with GPP; however, there is minimal research documenting characteristics of GPP flares.^{4,6}
- The objective of this study is to characterize flare episodes in GPP and their treatment.

METHODS

- This retrospective descriptive study included adult patients with GPP (ICD-10 code L40.1) identified in the Optum[®] de-identified electronic health record (EHR) data between 1 July 2015-30 June 2020.
- The index GPP diagnosis was the first occurrence in the EHR with no coded history of GPP for at least one year prior.
- Only patients with at least 12 months of health care activity documented in the EHR after the index diagnosis and with notes available in the EHR were included in the study.
- EHR "terms" refer to signs, diseases, and symptoms (SDS) documented, and "attributes" are descriptions of the SDS terms. Categories were developed to capture like words of the same concept. Each health care visit beginning on or after the index date of GPP diagnosis with documented notes that met at least one of the following criteria were considered a documented flare in the EHR.
 - 1. For visits with a primary diagnosis of GPP (ICD-10 code L40.1):
 - a. An encounter with place of service = 'EMERGENCY PATIENT', 'OBSERVATION PATIENT', 'INPATIENT', or 'URGENT'.
 - **b.** Any term in the "Flare" category
 - c. Any term in the "Pustule/Lesion" category plus any flare attribute
 - d. Any term in the "Rash" category plus any flare attribute

 - e. Any term in the "Other GPP symptoms" category plus any flare attribute 2. For dermatology-related visits (i.e., type of provider was a dermatologist or primary reason for visit was any skin-related diagnosis defined by ICD-10 L* or R2* code):
 - a. Any term in the "Flare" category AND any term in the "Pustule/Lesion" category
 - b. Any term in the "Pustule/Lesion" category plus any flare attribute
- Flare episodes were defined as consecutive days that a flare was documented in the EHR and were characterized by the frequency of occurrence per patient, the setting of care where they were identified, the type of specialist managing the episode, associated symptoms, and the treatments before, during, and after the episode.

RESULTS

• Of the 48.6 million patients with EHR notes available, 1,535 patients with GPP were identified, and 271 patients had at least one flare episode documented in their EHR and accounted for a total of 513 flare episodes during the study period. (Patients' characteristics - Table 1, Figure 1)

TABLE 1 – Race and Ethnicity of Patients					
Race	Ethnicity	# Patients	% Patients		
African American	Hispanic	4	0.3%		
	Non-Hispanic	115	7.5%		
	Unknown	3	0.2%		
Asian	Hispanic	3	0.2%		
	Non-Hispanic	23	1.5%		
	Unknown	2	0.1%		
Caucasian	Hispanic	47	3.1%		
	Non-Hispanic	1,181	76.9%		
	Unknown	55	3.6%		
Other/Unknown	Hispanic	31	2.0%		
	Non-Hispanic	40	2.6%		
	Unknown	31	2.0%		



Age 18-64

Age 65+



FIGURE 1 – Number of Patients at Age of Index GPP Diagnosis

- Half of GPP flares were identified in the outpatient setting (53%), followed by the inpatient setting (36%), and ER (9%) (Figure 2)
- In the outpatient setting, most flares were treated by dermatologists (73%), followed by rheumatologists (10%) and primary care providers (9%) (Figure 2)



- Majority of flares occurred within one month of initial GPP diagnosis. (Figure 3) • Over half of the flare episodes (58.3%) occurred on the same day as the index GPP diagnosis
- indicating that they were likely seeking care for a new GPP diagnosis based on a flare. (Figure 3)





• Majority experienced one flare episode during follow-up (average follow up was 724.8 days [median=698 days]) (Figure 4)





The most common signs/symptoms documented during flare episodes were pain (61% of flare episodes) followed by rash (46%), and fever (45%). (Figure 5)

FIGURE 5 – Commonly Used Terms Documented in a Flare Episode



Presented at EADV 30th Congress, 29 Sept – 2 Oct 2021

Specialist treating flare episode in outpatient* setting 9% 10% Primary care Rheumatologist 73% Dermatologist Specialist type

5%	4%	3%	1%
months	19-24 months	2-3 years	>3 years

- episodes. (Figure 6)
- days after a flare episode. (Figure 6)

FIGURE 6 – Common Treatments During Flare Episodes Docum

TOPICAL STEROID OTHER TOPICAL ORAL CORTICOSTEROID ORAL RETINOID **ORAL OTHER** PHOTOTHERAPY **TNF INHIBIT** PDE-4 INHIBIT OPIOIDS



* IL INHIBITORS include IL-17, IL12/23 and IL23 inhibitors

CONCLUSIONS

- steroids.
- Over one-third of GPP flares were identified in an acute care setting.
- Most common treatment during a flare episode was topical steroids, and one-quarter of episodes had no documented dermatological treatment.
- Treatment with opioids was common during flare episodes indicating the need for pain management.

LIMITATIONS

- number of GPP episodes.
- episodes are likely to be higher severity than those not documented.
- actually taken by the patient.
- Duration of flare episodes cannot be accurately determined in EHR data.

REFERENCES

- *Dermatol Venereol*. 2017;31(11):1792-1799. doi:10.1111/jdv.14386.
- *Immunol*. 2019;143(3):1021-1026. doi:10.1016/j.jaci.2018.06.038.
- doi:10.2340/00015555-3388.
- in a nationwide inpatient database in Japan. J Am Acad Dermatol. Published online 8 June 2021. doi:10.1016/j.jaad.2021.06.008
- United States. *Curr Med Res Opin*. 2021;37(5):735-742. doi:10.1080/03007995.2021.1894108

: We would like to thank Maya Hanna for her contributions to the study. Acknowled

The study was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). The authors met criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). CL Zema is a contractor to BIPI. WC Valdecantos is a full-time employee of BIPI. J Weiss and B Krebs are employees of Optum, a contractor to BIPI for this study. A Menter is an investigator for AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Genentech, Janssen Biotech, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, and Wyeth; receives research funds from AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Genentech, Janssen Biotech, LEO Pharma, Merck, Pfizer, Symbio/Maruho, and Syntrix; and is an advisor, consultant, and/or speaker for and received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth, and XenoPort.

The most common dermatologic treatment during a flare episode was topical steroids (35% of flare episodes) followed by other oral treatments, such as methotrexate, cyclosporine, and tacrolimus (13%), and oral corticosteroids (11%). Opioids were prescribed during 21% of flare

One-quarter of all flare episodes had no dermatologic treatment 30 days before, during or 30

nented in the	e EHR	
14%	22%	35%
3%		Up to 30 days prior to episode
		During episode
		Up to 30 days after episode
14%	21%	
17/0	Percentage of flare episodes	

• There is significant unmet need for the treatment of GPP flares as evidenced by patients seeking treatment in inpatient and ER settings as well as the lack of advanced treatments beyond topical

• Due to the rarity and lack of awareness of GPP, it is likely that additional patients with true GPP remain undiagnosed or are miscoded with another form of psoriasis. In order to ensure that the

study captured patients with GPP, only patients coded with a GPP diagnosis were included. • The algorithm to identify GPP flares was intentionally conservatively designed to ensure that only flares due to GPP were identified. Thus, it is likely that the methodology underestimates the

• Patient surveys suggest that patients do not always seek medical treatment for flares. This study only identifies patients with GPP flares documented in their EHR and underestimates the true number of patients with GPP who flare and the number of flare episodes. Also, documented flare

• In the EHR data, the treatments are based on prescriptions written or administered in the office/facility. Written prescriptions may not represent whether the prescription was filled and/or

. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad

. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin

Bachelez H. Pustular Psoriasis: The Dawn of a New Era. Acta *Derm Venereol*. 2020;100(3):adv00034. Published 2020 Jan 30.

. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi:10.1080/1744666X.2019.1708193. Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients

6. Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the

